Abstracts tagged "autoimmune diseases"

Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Christina Donath¹, Sara Kahlown¹, Ryan Soares², Kamal Gautam², Mariam Saleh³, Banki Katalin⁴ and Andras Perl⁵, ¹SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ²SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, ³SUNY Upstate University Hospital, Syracuse, NY, ⁴SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ⁵SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
Abstract Number: 0257 • ACR Convergence 2024
High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action
Jaspreet Bhatti¹, Kyu-In Lee¹, Arushika Yedla¹, Julia Ash¹, James Miceli¹, Kirk Sperber¹ and Amy Wasserman², ¹Westchester Medical Center, Valhalla, NY, ²Westchester Medical Center, Valhalla
Background/Purpose: Strongyloides Stercoralis is a human intestinal nematode widely found in tropical and subtropical regions that frequently causes chronic and asymptomatic infection (Table 1). Immunosuppression in a host…
Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Gianluca sambataro², iazsmin Ventura³, Francisca Bozan⁴, Eduardo Dourado⁵, Sara Faghihi-Kashani⁶, Aravinthan Loganathan⁷, Daphne Rivero Gallegos⁸, Akira Yoshida⁹, Giovanni Zanframundo¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Andrew Mammen¹⁸, Neil McHugh¹⁹, Frederick Miller²⁰, Carlomaurizio Montecucco²¹, Antonella Notarnicola²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo A. Scire²⁶, Albert Gil-Vila²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²University of Catania, Catania, Italy, ³Section of Rheumatology, University of Chicago, Chicago, IL, ⁴Hospital Clinico Universidad de Chile, Santiago, Chile, ⁵Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸INER, Ciudad de México, Mexico State, Mexico, ⁹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹⁰Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸NIH, Bethesda, MD, ¹⁹University of Bath, Bath, United Kingdom, ²⁰NIH, NIEHS, Chapel Hill, NC, ²¹IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²²Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Universitat Autònoma of Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Löhr⁸, Nicolas Schleinitz⁹, Lingli Dong¹⁰, Hisanori Umehara¹¹, Marco Lanzillotta¹², Zachary Wallace¹³, Mikael Ebbo¹⁴, George Webster¹⁵, Ferran Martinez Valle¹⁶, Manu Nayar¹⁷, Vinciane Rebours¹⁸, Cory Perugino¹⁹, Xinxin Dong²⁰, Yanping Wu²⁰, Nishi Rampal²⁰ and Daniel Cimbora²⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Ospedale San Raffaele, Milan, Italy, ⁶University of Occupational and Environmental Health, Osaka, Japan, ⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹¹Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, ¹²IRCCS Ospedale San Raffaele, Milano, Italy, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴Aix-Marseille Université, Marseille, France, ¹⁵University College Hospital London, London, United Kingdom, ¹⁶Vall d’Hebron Hospital, Barcelona, Spain, ¹⁷Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Beaujon Hospital, Université Paris-Cité, France, ¹⁹Massachusetts General Hospital, Boston, MA, ²⁰Amgen Inc., Thousand Oaks, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 0860 • ACR Convergence 2024
Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
Xiangyi Shen¹, Xu Jiang², Yangzhige He² and Huaxia Yang³, ¹Tsinghua University, Beijing, China, ²National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 1107 • ACR Convergence 2024
Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Carine Moezinia¹, Jan Nouza², Beatrice Hornstein-Lasry², Luai Kawar², Asim Khan² and Jessica Manson², ¹University College London Hospital, London, England, United Kingdom, ²University College London Hospital, London, United Kingdom
Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
Abstract Number: 1304 • ACR Convergence 2024
Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents
Dania Kaur¹, Fizza Zulfiqar², Akanksha Sharma³, Muhammad Bilal⁴, Rida Fatima⁴ and Abhinav Vyas⁵, ¹North Alabama Medical Center, Muscle Shoals, AL, ²Trinity Health Oakland/Wayne State University, Pontiac, MI, ³UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Vanderbilt University Medical Center, Nahville, TN
Background/Purpose: Testing for antinuclear antibodies (ANA) is essential for diagnosing autoimmune and rheumatologic diseases. The testing has become increasingly popular in primary and specialized clinics,…
Abstract Number: 1533 • ACR Convergence 2024
Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Shrishti Tyagi¹, Kevin Hart¹, Ryan Eberwine², Angus Sinclair¹, Albert Candia¹, Bruce Keyt¹, Merle Elloso², Maya Kotturi¹ and Mary Beth Harler¹, ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
Abstract Number: 1659 • ACR Convergence 2024
Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Koen Venken¹, Matthias Jarlborg¹, Frederik Stevenaert², Thomas Malfait³, Carolien Vlieghe¹, Yann Abraham², Teddy Manuello¹, Tine Decruy¹, Stijn Van Hee¹, Hans Wils², Pieter Peeters², Philippe Carron⁴, Filip Van den Bosch³, Viggo Van Tendeloo², Bart Lambrecht¹, Ruth Wittoek⁵, Peggy Jacques⁶ and Dirk Elewaut⁷, ¹VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, ²Janssen Research and Development, Beerse, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴UZ Gent, Gent, Belgium, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ⁶University Hospital of GHent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
Abstract Number: 1787 • ACR Convergence 2024
Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis
Andrea Daamen¹, Kathryn Kingsmore², Prathyusha Bachali³, Nan Shen⁴, Amrie Grammer⁵ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, ³AMPEL BioSolutions, Redmond, WA, ⁴Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁵AMPEL LLC, Charlottesville, VA
Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
Abstract Number: 1861 • ACR Convergence 2024
CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice
Yuzo Koda¹, Piruzyan Mariam¹, Sota Fujimori¹, Ryota Sato² and Sayuka Kato¹, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Brighton, MA
Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].